With every change in administration, businesses and practitioners wonder what the new administration will mean for antitrust enforcement in the ...

A Leerink analyst says CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits ...

CVS Health is seeing signs of stabilization in key business areas, prompting Leerink Partners to upgrade the stock from Market Perform to Outperform and raise its price target to $75 per share in a ...

As prescription drug prices continue to spiral and federal efforts to control them stall, state lawmakers are focusing on ...

Shares of CVS Health Corp. continued climbing premarket Thursday after a blockbuster session driven by stronger-than-expected quarterly earnings. The stock surged nearly 15% on Wednesday, marking its ...

BofA raised the firm’s price target on CVS Health (CVS) to $75 from $63 and keeps a Buy rating on the shares. Aetna can add $3-$4 per share of ...

CVS Health Corporation reported financial results for the fourth quarter and full year of 2024, highlighting challenges ...

CVS Health downgraded to Hold due to political risks, declining cash flow, and industry battles despite strong Q4 sales and a ...

California Gov. Gavin Newsom and state legislators in Sacramento seem to agree: Prescription drug prices are too high.

U.S. stock futures were mixed on Thursday after a hotter-than-expected January inflation print, which was released on Wednesday.

CVS Health (CVS) stock soared about 15% yesterday after posting upbeat fourth-quarter results, with revenues and earnings surpassing analysts’ ...

CVS Health Corp issued an optimistic guidance for 2025 stemming from the expected recovery in its insurance business — ...